COVID-19 Associated Mucormycosis: Scoping Review Protocol

Salman Hussain¹, Harveen Baxi², Abanoub Riad^{1,3} Jitka Klugarová^{1,3}, Radim Líčeník¹, Miloslav Klugar^{#1,3}

¹Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic

***Corresponding author**

Dr. Miloslav Klugar,

Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic

Email: klugar@med.muni.cz

²Independent Researcher, New Delhi, India

³Department of Public Health, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic

Abstract

Background and Objective: Mucormycosis, a serious and rare fungal infection, has

occurred concurrently in COVID-19 patients globally. Mucormycosis is associated with a

high risk of all-cause mortality, with mortality depending on body site infected, fungus type,

and the patient's overall condition. This deadly fungal infection is quite difficult and

expensive to treat. Therefore, this scoping review aims to map all the empirical evidence on

the COVID-19 associated mucormycosis with a special focus on clinical presentation,

treatment, and patient outcomes.

Methods: The proposed scoping review will be developed by adhering to the JBI

methodology for scoping reviews and will be reported as per the Preferred Reporting Items

for Systematic Reviews and Meta-analyses for Scoping Reviews (PRISMA-ScR). A detailed

search strategy has already been utilized to locate both published and unpublished studies.

Literature search was carried out in three phases. PubMed, Scopus, Cochrane, Google scholar

was searched. We will include all those studies which are presenting mucormycosis cases in

COVID-19 positive patients. Data will be extracted in a pre-designed data extraction sheet

and risk of bias will be assessed using JBI critical appraisal tool. The primary outcome will

be to summarize the clinical presentation, treatment, and patient outcomes in COVID-19

2

associated mucormycosis. Data will be presented in tabular form.

Keywords: COVID-19; Fungal Infection; Mucormycosis; Scoping Review, Systematic

Review

OSF registration number: osf.io/438sm

Introduction

The COVID-19 outbreak, caused by severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2), has infected more than 164 million people globally with approximately 3.4 million deaths.[1] COVID-19 patients often have several co-morbidities including diabetes.[2] Ample evidence has proved patients with co-morbidities to be at a higher risk of ICU admissions and mortality than those without comorbidities.[3-5] COVID-19 patients in severe stages (admitted to ICUs), are prescribed high-doses of steroids as a life saving measure.[6] Steroids, supress the immune system (decrease in CD4 + T and CD8 + T cells) to fight against the inflammation caused by the virus, thereby creating a favourable environment for other opportunistic infections.[6, 7] Mucormycosis, a serious and rare fungal infection, has occurred concurrently in COVID-19 cases globally.[8] Mucormycosis, also known as black fungus, is an invasive fungal infection most commonly caused by fungi-Rhizpous.[9] This deadly fungal infection is quite difficult and expensive to treat. At the moment more detailed evidence on the clinical presentation, treatment and patient outcomes is required. The preliminary search for existing scoping reviews was performed in Epistemonikos, PROSPERO, Open Science Framework, Cochrane Library and JBI Evidence Synthesis and no previous scoping reviews were identified.

Objective

This scoping review will be conducted to map all empirical evidence on the COVID-19 associated mucormycosis, with a special focus on clinical presentation, treatment, and patient outcomes.

Methods

The proposed scoping review will be developed by adhering to the JBI methodology for scoping reviews and will be reported as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses for Scoping Reviews (PRISMA-ScR).[10, 11]

Search strategy

A detailed search strategy has already been utilized to locate both published and unpublished studies. Literature search was carried out in three phases. First, an initial limited search was undertaken in PubMed, using keywords and index terms related to COVID-19, SARA-CoV2, mucormycosis, and black fungus. An analysis of the text words contained in the title and abstract and the index terms used to describe the articles was then followed. A second search

using all identified keywords and index terms was conducted in all included databases (PubMed, Scopus, Cochrane, Google scholar). Refer Appendix 1 for the detailed search strategy. Third, the reference lists of all studies that met the inclusion criteria were checked for other additional records followed by citation tracking. Gray literatures were located using Cochrane COVID-19 study register, bioRxiv, and medRxiv. COVIDENCE will be use to complete this scoping review (Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org).

Study selection

Two independent reviewers (SH and HB) will be screening all the retrieved articles in alignment to the inclusion criteria. In the initial screening phase, articles will be selected based on the title and abstract scanning. Then, in the second phase, full-text screening will be performed for the final inclusion of articles in the scoping review. PRISMA flow diagram will depict each stage of the study selection process.

Inclusion criteria

Participants: Patients with confirmed COVID-19 (RT-PCR) and mucormycosis (either histologically or microbiologically confirmed)

Concept: This review will include all studies that describe the clinical presentation, treatment, and patient outcomes.

Context: We will focus on the clinical studies discussing the clinical presentation, treatment, and patient outcomes in COVID-19 patients with mucormycosis.

Type of sources: We will include descriptive studies (case-report, case-series, cross-sectional) and epidemiological studies.

We will exclude:

- Non-English language studies
- Studies with no clear information about mucormycosis and other criteria's
- Systematic reviews, narrative reviews, editorials, opinions, correspondence, and study protocols will be excluded

Assessment of risk of bias

The methodological quality of the selected studies will be evaluated using the Jonna Briggs Institute (JBI) critical appraisal tool. An appropriate JBI risk-of-bias tool will be adapted according to the study design of the studies qualified for inclusion in this scoping review.

Depending on the response of each domain of the tool, the study will be classified as high, low or unclear risk of bias.

Data analysis and presentation

Two reviewers (SH and HB) will independently extract the data in a pre-designed data extraction template. Following information will be extracted from all eligible studies qualified for inclusion: Study author, year of publication, country, study design, characteristics of the population (age, sex), sample size, co-morbidities, treatment for COVID-19, symptoms of mucormycosis, diagnosis of mucormycosis, identification of fungal species, treatment for mucormycosis, and patient outcomes. Data will be descriptively presented for each outcome.

Funding: Salman Hussain is supported from Operational Programme Research, Development and Education –Project, Postdoc2MUNI "(No. CZ.02.2.69/0.0/0.0/18_053/0016952)"; Miloslav Klugar, Abanoub Riad, Radim Líčeník and Jitka Klugarová are supported by the INTER-EXCELLENCE grant number LTC20031 — "Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic". The work of Abanoub Riad is also supported by Masaryk University grants MUNI/IGA/1543/2020 and MUNI/A/1608/2020.

References

- [1] WHO Coronavirus (COVID-19) Dashboard. Avaiable at: https://covid19.who.int/. Accessed on 29th May 2021.
- [2] J. Yang, Y. Zheng, X. Gou, K. Pu, Z. Chen, Q. Guo, R. Ji, H. Wang, Y. Wang, Y. Zhou, Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis, Int J Infect Dis 10 (2020).
- [3] S. Hussain, H. Baxi, M.C. Jamali, N. Nisar, M.S. Hussain, Burden of diabetes mellitus and its impact on COVID-19 patients: a meta-analysis of real-world evidence, Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14(6) (2020) 1595-1602.
- [4] P. Ssentongo, A.E. Ssentongo, E.S. Heilbrunn, D.M. Ba, V.M. Chinchilli, Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis, PloS one 15(8) (2020) e0238215.
- [5] W. Tian, W. Jiang, J. Yao, C.J. Nicholson, R.H. Li, H.H. Sigurslid, L. Wooster, J.I. Rotter, X. Guo, R. Malhotra, Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis, Journal of medical virology 92(10) (2020) 1875-1883.
- [6] A.K. Singh, S. Majumdar, R. Singh, A. Misra, Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective, Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14(5) (2020) 971-978.
- [7] A.I. Ritchie, A. Singanayagam, Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?, The Lancet 395(10230) (2020) 1111.
- [8] R.I. El-Herte, T.A. Baban, S.S. Kanj, Mucormycosis: a review on environmental fungal spores and seasonal variation of human disease, Adv Infect Dis 2(3) (2012) 76-81.
- [9] A.S. Ibrahim, B. Spellberg, T.J. Walsh, D.P. Kontoyiannis, Pathogenesis of mucormycosis, Clinical Infectious Diseases 54(suppl_1) (2012) S16-S22.

- [10] M. Peters, C. Godfrey, P. McInerney, C.B. Soares, H. Khalil, D. Parker, Methodology for JBI scoping reviews, The Joanna Briggs Institute Reviewers Manual 2015, Joanna Briggs Institute2015, pp. 3-24.
- [11] A.C. Tricco, E. Lillie, W. Zarin, K.K. O'Brien, H. Colquhoun, D. Levac, D. Moher, M.D. Peters, T. Horsley, L. Weeks, PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation, Annals of internal medicine 169(7) (2018) 467-473.